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Patients undergoing chronic dialysis often display sustained elevations of inflammation markers 
and also have a high prevalence of depressive symptoms. Although multiple studies demon-
strated cross-sectional associations between inflammation markers and depressive symptoms in 
this patient group, longitudinal associations have not been examined. We therefore investigated 
whether longitudinal associations exist between inflammation markers and depressive symptoms 
in chronic dialysis patients.  
 
Methods  
Data of three consecutive measurements of an observational, prospective cohort study among 
chronic dialysis patients were used. At baseline, 6 months and 12 months follow-up, patients 
completed the Beck Depression Inventory (BDI) and inflammation markers (HsCRP, IL-1β, IL-
6, IL-10, and TNFα) were measured. We examined cross-sectional associations between in-
flammation markers and depressive symptoms using linear regression models. The longitudinal 




A total of 513 patients were included. Cross-sectional associations were found between HsCRP 
and depressive symptoms at baseline (β= 0.9 (CI: 0.4-1.4)) and 6 months follow-up (β= 1.1 (CI: 
0.3-2.0)), and between IL-1β and depressive symptoms at 6 months follow-up (β= 1.3 (CI: 0.8-





1.8)) and 12 months follow-up (β= 1.2 (CI: 0.4-1.9)). Inflammation makers (HsCRP, IL-6, IL-1β, 
IL-10 and TNFa) at baseline were not associated with depressive symptoms at follow-up and 
vice versa.  
 
Conclusion  
We confirmed the presence of cross-sectional associations between inflammation markers and 
depressive symptoms in chronic dialysis patients, but with our longitudinal data we found no 
longitudinal associations. This supports an associative instead of a causal relationship between 
inflammation and depressive symptoms. 
 
Keywords:  
chronic dialysis patients; depressive symptoms;  inflammation markers; longitudinal associations 
 
Acronyms: 
BDI= Beck Depression Inventory; BMI= Body Mass Index; GFR= Glomerular Filtration Rate; 
HsCRP= High sensitivity C-reactive protein; HPA-axis= Hypothalamic-Pituitary-Adrenal-axis; 
IL= Interleukine; IDO= indoleamine-2,3-dioxygenase; M0= Measurement at baseline; M6= 
Measurement at 6 months follow-up; M12= Measurement at 12 months follow-up; TNFα= Tu-
mor necrosis factor α; 5-HT= Serotonine.   
  






Chronic dialysis patients are known for the presence of a chronic inflammatory state
1
 and for a 
high prevalence of depressive symptoms
2
. Depressive symptoms are associated with morbidity 
and both short-term and long-term mortality in dialysis patients
3-6
. Also higher levels of inflam-
mation markers (especially CRP) have been found to be associated with both higher morbidity 
and mortality
7-10
. Multiple studies have examined cross-sectional associations between high le-
vels of inflammation markers and depressive symptoms in dialysis patients
11
. A recent systemat-
ic review demonstrated a mixed outcome of these studies: with some studies demonstrating sig-
nificant cross-sectional associations, while other studies failed to
11
. Besides, effect sizes in pre-
vious studies are mostly small and the existence of an association is still uncertain
11;12
. Long 
term associations between inflammation markers and depressive symptoms and especially the 
direction of this association have to the best of our knowledge not been examined in chronic di-
alysis patients. 
 
 The direction of the relationship between inflammation and depression has been studied 
in the general population
13-17
. Some studies demonstrated that depression may lead to subsequent 
inflammation
13;14;17
, whereas other studies have found that inflammation may precede 
depression
18-21
. One study found evidence for a bidirectional relationship over a 1 to 2 year fol-
low-up period
16
. On the basis of these results the cause-effect relationship between inflammation 
and depression could run in either direction.  
 
The exact mechanism explaining the link between inflammation and depressive symp-
toms is not clear
22
. Theories have been formulated to explain both directionalities. On the one 





hand, inflammation could cause subsequent depression via activation of the enzyme indolea-
mine-2,3-dioxygenase (IDO), which degrades tryptophan (the precursor of serotonin) into kynu-
renine leading to low serotonin levels
23
. It is known that lower concentrations of serotonin in the 
central nervous system may cause depressive symptoms
24
. This theory is especially plausible in 
the dialysis population as these patients are not only known for high levels of inflammation, but 
also for low tryptophan levels and high kynurenine levels
25;26
. Also, the degradation products of 
tryptophan might play a role, as these degradation products lead to oxidative stress and impair 
the mitochondrial metabolism and trigger apoptosis
27
. Inflammation could also cause depression 
via hyperactivity of the Hypothalamic-Pituitary-Adrenal (HPA)-axis
28
. On the other hand, de-
pression may cause inflammation by reducing the sensitivity of the immune system to glucocor-
ticoids responsible for terminating the inflammatory response
29;30
.  Furthermore, clinical depres-
sion has also been linked to diminished activation of the parasympathetic nervous system, while 




 As the inflammatory state of dialysis patients is more pronounced than that of healthy 
individuals
31
, it is uncertain whether results found in the general population can be extrapolated 
to the dialysis population. Therefore, the aim of this study is to examine whether longitudinal 
associations exist between inflammation markers and depressive symptoms in chronic dialysis 
patients. The second aim is to examine the directionality of the inflammation-depression associa-
tion among chronic dialysis patients. We hypothesized that based on the theories described 
above, also in the dialysis population a bidirectional relationship between inflammation and de-
pression may be found. 
  







Data from the DIVERS study (Depression related factors In dialysis patients with Various Eth-
nicities and Races Study) were used. DIVERS is an observational, prospective cohort study of 
chronic dialysis patients in four urban teaching hospitals and one university hospital in The 
Netherlands.    
 
Both prevalent and incident dialysis patients were included. Inclusion started in June 2012 and 
ended in December 2013 for prevalent patients. For incident patients the inclusion ended in De-
cember 2016. Included patients were assessed biannually until death, kidney transplantation, a 
transfer to a non-participating center, or discontinuation of participation because of motivational 
reasons.   
 
Inclusion criteria were: ≥18 years of age, undergoing dialysis treatment (hemodialysis or 
peritoneal dialysis) for at least 90 days, and being able to complete a questionnaire in Dutch, 
English, Turkish or Moroccan Arabic. Patients with cognitive impairments (e.g. dementia) were 
excluded.  
 
For the current study we used the measurements at baseline (M0), 6 months (M6) and 12 months 
(M12) follow-up until December 2014. At each time point patients completed a questionnaire 
and a blood sample was drawn. For hemodialysis patients the blood sample was taken imme-
diately prior to a dialysis session and for peritoneal dialysis patients at an outpatient visit.  
 





The DIVERS study was approved by the medical ethics committee of the VU University 
Medical Center (approval number: 2010/064). All patients gave their written informed consent 
prior to study inclusion.  
 
Depressive symptoms 
Depressive symptoms were assessed at baseline, 6 months and 12 months follow-up with the 
Beck Depression Inventory-II (BDI)
32;33
. The BDI is a 21-item self-report scale, with items 
scored on a scale of 0 to 3. Summed scores range from 0 to 63 and higher scores indicate more 
severe depressive symptoms.  The BDI has been validated in one of the participating centers of 
the DIVERS study
34
. This study found a cut-off point of 13 for the detection of depression, with 
a sensitivity of 0.75 and specificity of 0.90. The cut-off point was only used to estimate the pre-
valence of depressive symptoms in this patient group. In the regression analyses the continuous 
outcome was used.  A distinction can be made in cognitive-affective and somatic symptom 
scores. The cognitive-affective symptom score was calculated by summing BDI-II  items 1-14 
(sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-
dislike, selfcriticalness, suicidal ideation, crying, agitation, loss of interest, indecisiveness, 
worthlessness). The somatic symptom score was calculated by summing BDI-II items 15-21 






Inflammation markers were assessed at baseline, 6 months and 12 months follow-up (single 
measurement). Peripheral blood was collected before dialysis and all samples were immediately 





centrifuged. Serum aliquots were stored at -80  C until analysis. Baseline and follow-up serum 
samples were analyzed at the same time at the Department of Rheumatology & Clinical Immu-
nology (University Medical Center Groningen, The Netherlands). Several pro-inflammation cy-
tokines (HsCRP, IL-1β, IL-6, and TNFα) and the anti-inflammation cytokine (IL-10) were de-
termined by using the Magnetic Luminex Screening or Performance assay (R&D Systems, Ab-
ingdon, UK) according to the manufacturer’s instructions. Samples were measured using Lumi-
nex 100 System (Luminex, Austin, Tx, USA) and data were analyzed with StarStation software, 
version 2.3 (Applied Cytometry, Birmingham, UK).  
 
The detection range for HsCRP after dilution (1000x) is 0.116-28.244ug/mL. The detection 
range for the other inflammation markers after dilution (2x) is for IL-1β 0.67-2800pg/mL, for IL-
6 1.90-7800pg/mL, for IL-10 0.92-3800pg/mL and for TNF-α 1.52-6200pg/mL. The intra-assay 
coefficient of variation for HsCRP, IL-1β, IL-6, IL-10 and TNF- α is respectively 6.4, 5.3, 5.2, 




At baseline the following socio-demographic characteristics were collected: partnership/marital 
status (yes/no), having children (yes/no), educational level (low versus average/high), race 
(White, Asian, or Black), current smoking (yes/no), and current alcohol use (yes/no). From elec-
tronic medical records were collected: age, sex, dialysis modality (hemodialysis or peritoneal 
dialysis), dialysis vintage, Body Mass Index (BMI, weight/height
2
), primary kidney disease, 
comorbidities, anti-depressant use (yes/no), and residual diuresis . Dialysis vintage was deter-





mined in months on dialysis and a subdivision was made in incident (less than 6 months on di-
alysis) and prevalent patients (dialysis longer than 6 months). Primary kidney disease was classi-
fied according to the European Renal Association-European Dialysis and Transplant Association 
(ERA-EDTA) codes
37
 and divided into 4 groups (diabetes mellitus, glomerulonephritis, renal 
vascular disease, and other). The Davies comorbidity index
38
, was used to classify comorbidities 
in no, intermediate or severe comorbidity. Residual diuresis indicating remaining glomerular 
filtration rate (GFR), was defined as a urine production of >100 mL per day.  
 
Statistical analysis 
Participants were included if they had both a serum cytokine measurement and BDI score at one 
or more measurements (baseline or follow-up). 
 
Standard descriptive statistics were used to present baseline characteristics. To examine 
the internal consistency of the BDI we calculated crohnbach’s alpha for the BDI at all three time 
points on the non-imputed dataset. HsCRP, IL-1β, IL-6, and IL-10 were log transformed (natural 
logarithm) to normalize the distribution of the data. The change in inflammation markers and 
depressive symptom scores between time points was calculated by subtracting the mean values 
of the inflammation markers at M0 from M6, M0 from M12 and M6 from M12. All models were 
adjusted for the following confounders (collected at baseline): age, sex, education, race, smok-
ing, alcohol use, BMI, dialysis modality, primary cause of renal failure, comorbidities, residual 
diuresis, and dialysis vintage. 
  





First, cross-sectional associations were examined between inflammation markers and de-
pressive symptoms at M0, M6 and M12 by using univariate and multivariate linear regression 
analysis. Second, the longitudinal relationship between inflammation and depressive symptoms 
was assessed by using a linear mixed model. This method makes optimal use of the available 
data during follow-up, accounts for correlations in the repeated measures in one subject over 
time, and appropriately handles missing data. Again both directions between inflammation and 
depressive symptoms were analyzed and all time points were used. The mixed models were fit-
ted with a random intercept for participant and a repeated time effect. Models included the de-
terminant under study, time, and the interaction between the determinant under study and time as 
fixed effects. Compound symmetry was used as the covariance structure.   
 
Due to the log transformation of HsCRP, IL-1β, Il-6 and IL-10, the beta has to be inter-
preted at a different scale. Beta indicates differences in depressive symptoms related to 1 unit 
change in baseline log cytokine. Log (HsCRP) ranges from -7.87 to 4.83, log (IL-1β) from -
11.17 to 3.20, log (IL-10) from -9.02 to 4.83, log (IL-6) from -6.93 to 4.36, and BDI from 0 to 
56.  
 
To perform the analysis on complete datasets we imputed missing data with multiple im-
putation techniques (10 repetitions) in SPSS. With multiple imputation missing data are imputed 
by a value that is predicted using all other available patient characteristics
39
. We imputed missing 
socio-demographic and clinical data and missing values on the BDI and cytokines. We per-
formed both the linear regression analysis and linear mixed model on the imputed dataset.  
 






We performed sensitivity analyses to test the robustness of our data. First, we assessed the longi-
tudinal relationship between inflammation and depressive symptoms in patients with complete 
data on all three measurements for both cytokines and BDI score. Second, we also performed the 
analysis in the total patient group, without exclusion of patients who did not have a cytokine and 
depressive symptoms measurement at at least one time point. Third, we made a subdivision in 
incident and prevalent patients and performed the linear mixed model in both groups. We also 
performed the linear mixed model separately for patients with and without diabetes mellitus and 
for hemodialysis and peritoneal dialysis patients. We also performed the linear mixed model with 
the cognitive-affective and somatic symptom score as outcome and as predictor. Fourth, we ex-
amined the longitudinal association between inflammation markers and depressive symptoms by 
using linear regression models. Namely, (a) the association between baseline inflammation and 
depressive symptoms at 6 or 12 months follow-up was modeled, adjusted for depressive symp-
toms at baseline, and (b) the association between baseline depressive symptoms and inflamma-
tion at 6 or 12 months follow-up was modeled, adjusted for inflammation markers at baseline. 
Fifth, using the linear mixed model, imputation is not necessary as the model appropriately han-
dles missing data. We performed the linear mixed model on both our imputed and non-imputed 
dataset. Sixth, we also performed a linear regression analysis between change in inflammation 
marker between time points and change in depressive symptom score between time points (M0-
M6, M0-M12 and M6-M12) for patients with complete data on the three measuring points. Final-
ly, by using a multiple imputation set only unstandardized coefficients are reported. We trans-
formed our variables (predictors and outcome)  into standardized variables and performed both 
the linear regression model and linear mixed model using the standardized variables to be able to 









A total of 548 chronic dialysis patients were included in the DIVERS study until December 
2014. For the present analysis we included 513 patients who had at least a serum cytokine mea-
surement and BDI score at one time point. One hundred ninety seven patients (38%) had com-
plete data on all three time points for both cytokines and BDI scores, 162 patients (32%) had 
complete data on two time points, and 154 patients (30%) had complete data on one time point. 
Crohnbach’s alpha for the BDI was at all three time points 0.9.  
 
Baseline characteristics of the study sample are shown in table 1 for both the full sample (513 
patients) and the sample with complete data on all three time points (197 patients) . The average 
age of the full sample was 64 (±15)  years of age and 61% were male. Eighty nine percent were 
treated with hemodialysis and 32% were incident dialysis patients. The median dialysis vintage 
was 18 months. The prevalence of depression was 44% and 10% of the patients were treated 
with anti-depressants. Table 2 shows the median or mean level of the inflammation markers on 
the different time points. Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/PSYMED/A521, shows the change in inflammation markers and depressive 
symptom scores between the different time points.  
 
Cross-sectional associations between inflammation markers and depressive symptoms 
Table 3 shows cross-sectional associations between inflammation markers and depressive symp-





toms at baseline, 6 months follow-up, and 12 months follow-up. At baseline HsCRP was signifi-
cantly associated with depressive symptoms (β= 0.9 (CI: 0.4-1.4)), this association remained 
similar after adjustment for confounders. At 6 months HsCRP (β= 1.1 (CI: 0.3-2.0)),  and IL-1β 
(β= 1.3 (CI: 0.8-1.8)), were significantly associated with depressive symptoms. After adjustment 
the associations were still significant for HsCRP (β= 1.0 (CI: 0.3-1.7)) and for IL-1β (β= 0.9 (CI: 
0.4-1.4)). At 12 months only IL-1β was significantly associated with depressive symptoms (β= 
1.2 (CI: 0.4-1.9)), also after adjustment this association was significant (β= 0.8 (CI: 0.01-1.6)).  
 
Longitudinal associations between inflammation markers and depressive symptoms 
Table 4 presents the longitudinal association between inflammation markers and depressive 
symptoms. Baseline inflammation markers (HsCRP, IL-6, IL-1β, IL-10 and TNFa) were not sig-
nificantly associated with depressive symptoms at follow-up. Baseline depressive symptoms 
were not significantly associated with inflammation markers (HsCRP, IL-6, IL-1β, IL-10 and 
TNFa) at follow-up.  
 
Sensitivity analyses  
In patients with complete data on all three measurements (N=197) we also found no significant 
longitudinal associations between inflammation markers and depressive symptoms (Supplemen-
tary Table 2, Supplemental Digital Content 2, http://links.lww.com/PSYMED/A522). Compara-
ble results were found in the total patient group (N=548) (data not shown). When dividing the 
patient group in incident (N=164) and prevalent (N=349) patients, we found no significant longi-
tudinal associations in both groups (data not shown). We found similar results for patients with 
(N=216) and without diabetes mellitus (N=297) (data not shown). When dividing hemodialysis 





patients (N=458) from peritoneal dialysis patients (N=55) we found no significant longitudinal 
associations in both groups (data not shown). By dividing the BDI symptom score in a cognitive-
affective symptom score and a somatic symptom score we did not find significant longitudinal 
associations either (data not shown). 
 
Examining the longitudinal association by using linear regression analysis we also found compa-
rable results. Baseline inflammation markers (HsCRP, IL-6, IL-1β, IL-10 and TNFa) were not 
associated with depressive symptoms at 6 months and 12 months follow-up, although baseline 
TNFa showed a trend towards a significant association with depressive symptoms at 6 months 
follow-up. Baseline depressive symptoms were not associated with inflammation markers 
(HsCRP, IL-6, IL-1β, IL-10 and TNFa) at 6 or 12 months follow-up. 
 
Performing the linear mixed model on the not imputed dataset also showed comparable results.  
In Supplementary Table 3, Supplemental Digital Content 3, 
http://links.lww.com/PSYMED/A523, the association between change in inflammation marker 
and change in depressive symptom score between the time points is shown for patients with 
complete data. The change in the level of IL-10 is significantly associated with change in depres-
sive symptoms between time point M6 and M12. For all other inflammation markers and time 
points no significant associations were found. Finally, in Supplementary Table 4, Supplemental 
Digital Content 4, http://links.lww.com/PSYMED/A524 and Supplementary Table 5, Supple-
mental Digital Content 5, http://links.lww.com/PSYMED/A525, standardized regression coeffi-
cients are shown for respectively the cross-sectional associations and the longitudinal associa-
tions between inflammation markers and depressive symptoms.   






To the best of our knowledge, this is the first study examining long-term associations between 
inflammation markers and depressive symptoms in chronic dialysis patients. Cross-sectional 
associations between inflammation markers and depressive symptoms were found, but with the 
present longitudinal data we found no longitudinal associations between inflammation markers 
and depressive symptoms. Therefore, the direction of the association between inflammation 
markers and depressive symptoms in chronic dialysis patients cannot be determined yet.  
 
 In this study, cross-sectional associations were found between inflammation markers and 
depressive symptoms at baseline, 6 months follow-up and 12 months follow-up. However, these 
associations differed per time point: a significant association between HsCRP and depressive 
symptoms was found at baseline and 6 months follow-up, while IL-1β was only significantly 
associated with depressive symptoms at 6 months follow-up and 12 months follow-up. These 
results  may explain why studies among chronic dialysis patients found mixed results. In a re-
view by Taraz et al
11
 including 23 studies only 11 studies found significant associations between 
inflammation markers and depressive symptoms. In those studies most significant associations 
with depressive symptoms were found for IL-6  and CRP. The use of different methods for the 
assessment of depressive symptoms and the use of different techniques for the analysis of plasma 
cytokine levels could be reasons for the lack of uniformity in the results of these previous 
studies
40
. However, despite the use of the same method for the assessment of depressive symp-
toms and of the same analysis techniques in also the same patient population we found varying 
results at the different time points. Therefore, the association between inflammation markers and 
depressive symptoms in chronic dialysis patients appears to be unstable and cross-sectional ana-





lyses may therefore provide mixed results that may reflect the involvement of several mechan-
isms in the pathogenesis of depression in chronic dialysis patients.  
 
 Bidirectional longitudinal associations between inflammation markers and depressive 
symptoms were not found in this study. When comparing associations (standardized coefficients 
in Supplementary Table 5, Supplemental Digital Content 5, 
http://links.lww.com/PSYMED/A525) in both directions, the associations seem equally strong. 
Our results are in contrast with earlier longitudinal reports in the general population where sig-
nificant longitudinal associations between inflammation and depression have been found. How-
ever, in these general population studies most regression coefficients were small, suggesting a 
rather small effect of inflammation on long-term depression and vice versa
22
. Also, varying asso-
ciations have been found in both directions and possible explanations for this variance may be 
different study populations studied, with different ethnicities, age, and sex. Another explanation 
could be that increased inflammation is part of a biologically specific subtype of depression
41
, 
and therefore, the longitudinal and cross-sectional associations are not always found. Further-
more, it is known that in chronic dialysis patients complaints of uremia overlap with somatic 
symptoms of depression, making it more difficult to measure depression. By using the BDI it is 
possible to separate the somatic symptoms of depression from cognitive-affective symptoms. 
However, when examining the association between inflammation markers with the cognitive-
affective symptom score of the BDI we did not find significant longitudinal associations either. 
In chronic dialysis patients also continuously varying cytokine concentrations may play a role, 
due to both the activation of leukocytes in hemodialysis releasing cytokines and due to removal 
of cytokines by dialysis treatment 
42
.  Finally, the relationship between inflammation and depres-





sion in chronic dialysis patients seems to be more associative instead of causal.  
 
 This study has several strengths, including the multicenter design, the prospective collec-
tion of data on inflammation markers and depressive symptoms at three different time points 
(providing the opportunity to examine the depression-inflammation relationship in two direc-
tions) and the measurement of five different inflammation markers (HsCRP, IL-1β, IL-6, IL-10, 
and TNFa) in a large cohort of dialysis patients. The study also has some limitations. Firstly, 
cross-sectional inflammation-depression studies showed smaller effect sizes when depression 
was measured with self-report questionnaires instead of diagnosing major depression by per-
forming a structured interview
43
. We measured the presence of depressive symptoms by using 
the self-reported BDI questionnaire. It cannot be excluded that longitudinal associations between 
inflammation and depression would be found if the diagnosis of depression was made by using a 
structured clinical interview. Secondly, part of our patients were lost to follow-up due to death, 
kidney transplantation, loss of motivation, or due to recent inclusion no repeated measurements 
were available yet. However, by using multiple imputation techniques we used all our available 
data to estimate the missing data. This results in the best estimations of study associations, with 
correctly estimated standard errors and confidence intervals
39
. Thirdly, we performed a single 
measurement of cytokines at each time point. Double measurements (optimally at 2 weeks 
apart)
44
  would provide more reliable measurements and stronger associations due to more accu-
rate estimates. However, most studies examining the link between inflammation and depression 
were based on a single measurement
17
. Fourth, because all patients already received dialysis 
treatment prior to the collection of the blood samples, we can only conclude that change in in-
flammatory response does not lead to change in depression scores over time or vice versa, but 





not that the onset of inflammation leads to the onset of depressive symptoms. As we included 
both incident and prevalent patients we were able to distinguish between patients receiving di-
alysis treatment for a short time (dialysis vintage between 3-6 months) or a longer time, but in 
both groups we found no longitudinal associations. Finally, the time interval of 6 and 12 months 
may be too short to develop depressive symptoms due to inflammation or vice versa. However, a 
study in the general population found significant associations between baseline inflammation and 




 In conclusion, cross-sectional associations between inflammation markers and depressive 
symptoms were found corroborating previous studies. No indications were found for longitudinal 
associations between inflammation markers and depressive symptoms in this population of 
chronic dialysis patients. So, in spite of the presence of a known chronic inflammatory state 
among chronic dialysis patients, this does not appear to cause the onset of depressive symptoms 
in the long term (6-12 months follow-up). These results support an associative rather than a 
causative relationship between inflammation and depressive symptoms in chronic dialysis pa-
tients.  
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Table 1. Baseline characteristics of  chronic dialysis patients 





Age, mean (SD) 64 (15) 66 (14) 
Sex, male % 61 59 
Partnership, partner % 52 51 
Children, yes % 78 75 
Education, low % 58 61 
Race   
   Caucasian, % 55 65 
   Asian, % 14 9 
   Black, % 31 26 
Smoking, yes % 19 22 
Alcohol use, yes% 26 28 
Clinical characteristics 
Dialysis modality, hemodialysis % 89 91 
Incident, yes % 32 20 
Months on dialysis, median (IQ) 18 (5-51) 26 (10-58) 
Body mass index kg/m2, mean (SD) 27 (6) 27 (6) 
Residual renal function % 67 60 
Primary cause of renal failure %   
  Diabetes Mellitus 24 24 
   Glomerulonephritis 11 11 
   Renal vascular disease 27 28 





   Other 38 37 
Davies comorbidity %   
   No 27 22 
   Intermediate 55 59 
   Severe 18 19 
Anti-depressants, yes % 10 8 
Prevalence depression, yes % 44 45 
 
 
Abbreviations: SD (standard deviation), IQ (interquartile range) 
  






Table 2. Inflammation markers and depressive symptoms at baseline, 6 months and 12 months fol-
low-up 
 M0 (N=495) M6 (N=358) M12 (N=286) 
HsCRP, mg/L, median (IQ) 2.5 (0.7-6.8) 5.4 (1.3-23.1) 2.6 (0.8-9.6) 
IL-1β, pg/mL, median (IQ) 0.06 (0.01-0.41) 0.01 (0.01-0.34) 0.01 (0.01-0.01) 
IL-6, pg/mL, median (IQ) 2.7 (1.5-4.8) 2.5 (1.5-4.5) 2.7 (1.7-5.3) 
IL-10, pg/mL, median (IQ) 0.34 (0.13-0.65) 0.29 (0.07-0.54) 0.32 (0.1-0.7) 
TNF-α, pg/mL, mean (SD) 21.4 (11.9) 19.7 (10) 25.1 (15) 
BDI >13 (%) 44 43 41 
BDI score, mean (SD) 13.1 (9.7) 12.8 (9.5) 12.6 (10.0) 
 
Abbreviations: SD (standard deviation), IQ (interquartile range), BDI (Beck Depression Inven-













Abbreviations: B= unstandardized coefficient 
* P ≤ 0.05 
Adjusted for: age, sex, education, race, smoking, alcohol, BMI, dialysis modality, primary cause 




Table 3. Cross-sectional associations between inflammation markers and depressive symptoms at baseline, 6 months 
and 12 months follow-up in 513 chronic dialysis patients 
 M0  M6  M12  
 B (95% CI) 
Unadjusted 
B (95% CI) 
Adjusted  
B (95% CI) 
Unadjusted 
B (95% CI) 
Adjusted 
B (95% CI) 
Unadjusted 




0.9 (0.4-1.4)* 0.9 (0.4-1.5)* 1.1 (0.3-2.0)* 1.0 (0.3-1.7)* 0.2 (-0.8-1.3) 0.2 (-0.6-1.1) 
IL6
L 
1.0 (-0.1-2.1)  0.8 (-0.3-2.0) 0.8 (-0.8-2.5)  0.8 (-0.6-2.1) 0.5 (-1.2-2.2)  0.5 (-1.1-2.0) 
IL1β
L 
-0.1 (-0.5- 0.3)  -0.2 (-0.6-0.3) 1.3 (0.8-1.8)*  0.9 (0.4-1.4)* 1.2 (0.4-1.9)*  0.8 (0.01-1.6)* 
IL10
L 
-0.3 (-0.8- 0.3) -0.2 (-0.7- 0.4) 0.7 (-0.4- 1.7)  0.6 (-0.2- 1.4) -0.3 (-1.2- 0.7) -0.02 (-0.8- 0.8) 
TNFa 0.01 (-0.1- 0.1) -0.01 (-0.1- 0.1) -0.003 (-0.2- 0.2) 0.003 (-0.1- 0.1) -0.1 (-0.2- 0.1) -0.04 (-0.1- 0.1) 








Abbreviations: B= unstandardized coefficient 
* P ≤ 0.05 
Adjusted for: depressive symptoms/inflammation marker at baseline and age, sex, education, 
race, smoking, alcohol, BMI, dialysis modality, primary cause of renal failure, comorbidities, 
residual diuresis, and dialysis vintage. 
Table 4. Linear mixed model in both directions between inflammation markers and depressive symptoms in 
513 chronic dialysis patients 
Predictor Outcome B (95% CI) 
Adjusted only for de-
pressive symptoms at 
baseline or inflammation 
marker at baseline 




 baseline Depressive symptoms -0.03 (-0.4- 0.4)  0.01 (-0.4-0.4) 
IL6
L
 baseline Depressive symptoms -0.1 (-0.8- 0.6) 0.3  (-0.4-1.1) 
IL1β
L
 baseline Depressive symptoms -0.2 (-0.5- 0.2) -0.1 (-0.4- 0.2) 
IL10
L
 baseline Depressive symptoms 0.1 (-0.3- 0.5) 0.2 (-0.2- 0.6) 
TNFa baseline Depressive symptoms -0.01 (-0.2- 0.1) 0.01 (-0.1- 0.1) 
Depressive symptoms baseline HsCRP
L 
-0.002 (-0.01-0.01) -0.002 (-0.01- 0.01) 
Depressive symptoms baseline IL6
L 
-0.001 (-0.01- 0.01) -0.002 (-0.01- 0.01) 
Depressive symptoms baseline IL1β
L 
-0.002 (-0.02- 0.02) -0.003 (-0.02-0.01) 
Depressive symptoms baseline IL10
L 
0.001 (-0.01- 0.02) 0.0003 (-0.01- 0.01) 
Depressive symptoms baseline TNFa -0.01 (-0.1- 0.04)  -0.02 (-0.1- 0.1) 
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